Half-year report · Q2
4483.TEDINET S100UQ55
Period2024-04-01 → 2024-09-30
Filed2024-11-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥19.2bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥32.4bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥13.7bn | 2023-04-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥3.3bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥3.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥6.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥2.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥4.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥2.7bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥2.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥2.7bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥136.1bn | at 2024-09-30 | Cons. | Assets IFRS |
| Total assets | ¥122.5bn | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥100.0bn | at 2023-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥63.7bn | at 2024-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥51.8bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥72.4bn | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥70.7bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥68.7bn | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥64.5bn | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥72.1bn | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥70.6bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥68.6bn | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥27.5bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥14.5bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥21.5bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥22.8bn | at 2023-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥10.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥17m | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥2.0bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥4.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥24.9bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥6.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥16.6bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥341m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥33.51 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥71.76 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥42.2 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥33.18 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥69.95 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥40.53 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 52.9% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 57.6% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 68.6% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 35
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥21m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥21m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥379m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥649m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥649m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥116m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥15.5bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥15.5bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥21m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥19.2bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥19.2bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥21m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥5.0bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥89m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥89m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥338m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥50m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥133m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥9.8bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥9.8bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥38m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.5bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.0bn |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥13.8bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥13.7bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥89m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥3.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 769
| Item | Context | Value | Unit |
|---|---|---|---|
| Condensed year to quarter end consolidated statement of profit or loss IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed year to quarter end consolidated statement of comprehensive income IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed quarterly consolidated statement of changes in equity IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed quarterly consolidated statement of cash flows IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes reporting entity condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes basis of preparation condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant accounting policies condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant accounting estimates and judgements condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes goodwill and intangible assets condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes share capital and other equity items condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes dividends condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes earnings per share condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes fair value of financial instruments condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes related parties condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes subsequent events condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |